Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biokine Therapeutics, a biotechnology company, has received a $1.2 million research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel.
Subscribe to our email newsletter
The funding will support a Phase I/IIa clinical study to test the safety and the efficacy of the company’s product, BKT140 as a therapeutic treatment for myeloma and other hematological diseases. Biokine also announced the initiation of this study at the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Amnon Peled, CEO and founder of Biokine, said: “This is an exciting and significant time for the scientists, development staff, and investors who have supported the project. It is our goal to help cure and relieve the suffering of those struck by this cruel disease. Early data indicates that BKT140 may help us realize this goal.”